While a lung cancer diagnosis was once considered an absolute death sentence, hope is growing as global survival statistics reveal a complex story shaped by early detection, advancing treatments, and geographical disparities.
Key Takeaways
- The overall 5-year relative survival rate for all lung cancer patients in the United States from 2014-2020 is 26.7%
- In Europe, the 5-year survival rate for lung cancer overall was 13.9% for patients diagnosed between 2000-2007
- The 5-year overall survival rate for lung cancer in Japan from 2006-2008 diagnoses is 32.1%
- The 5-year survival rate for localized lung cancer (all stages confined to primary site) in US SEER data 2014-2020 is 63%
- For regional stage lung cancer (spread to regional lymph nodes), the 5-year survival rate is 34% per SEER 2014-2020
- Distant stage lung cancer has a 5-year survival rate of 8% in US data from 2014-2020
- Adenocarcinoma histology lung cancer stage I 5-year survival is 92% post-resection
- Squamous cell carcinoma 5-year survival rate overall is 18% (SEER 2014-2020)
- Small cell lung cancer overall 5-year survival is 7%
- Women under 65 with NSCLC have a 5-year survival rate of 32%
- Men over 65 with lung cancer 5-year survival is 17% (SEER 2014-2020)
- Black Americans lung cancer 5-year survival 20% vs 27% for whites (2014-2020)
- Surgical resection patients have 5-year survival of 55% for early stage NSCLC
- Immunotherapy plus chemo for stage IV NSCLC median survival 22 months (KEYNOTE-189)
- Stereotactic body radiotherapy (SBRT) for stage I inoperable NSCLC 5-year survival 88%
Survival rates for lung cancer vary greatly by stage and treatment.
Demographic-Specific Survival Rates
1Women under 65 with NSCLC have a 5-year survival rate of 32%
Verified2Men over 65 with lung cancer 5-year survival is 17% (SEER 2014-2020)
Verified3Black Americans lung cancer 5-year survival 20% vs 27% for whites (2014-2020)
Verified4Women have higher 5-year lung cancer survival (27%) than men (22%) per SEER
Directional5Patients aged 65-74 have 5-year survival of 23% for lung cancer (US data)
Single source6Never-smokers lung cancer 5-year survival 30% higher than smokers
Verified7In Australia, females lung cancer 5-year survival 21% vs males 14% (2008-2012)
Verified8Elderly (>80 years) stage I NSCLC survival 5-year 55% post-surgery
Verified9Hispanic lung cancer patients 5-year survival 24% (SEER)
Directional10Asian Americans lung cancer 5-year survival 29% (SEER 2014-2020)
Single source11Patients under 50 years lung cancer 5-year survival 35%
Verified12Rural vs urban lung cancer survival disparity 5-year 18% vs 25%
Verified13Smokers diagnosed early NSCLC 5-year survival 25% lower than non-smokers
Verified14Women smokers lung cancer survival better by 5-10% than male smokers
Directional15Socioeconomic low quintile lung cancer 5-year survival 15% vs high 25%
Single source16Indigenous Australians lung cancer 5-year survival 12%
Verified17Octogenarians post-lobectomy stage I survival 5-year 70%
Verified18American Indian/Alaska Native 5-year survival 19% lung cancer
Verified19Females NSCLC 5-year survival 30% vs males 23% (SEER)
Directional20Age 45-54 lung cancer 5-year survival 28%
Single source21Pacific Islander lung cancer survival 5-year 24%
Verified22Former smokers 5-year survival 25% vs current 15%
Verified23Urban high SES lung cancer survival 28%
Verified24Males under 65 5-year survival 29%
Directional25Comorbid COPD reduces survival by 15% in NSCLC patients
Single source26Young adults (<40) stage IV survival median 12 months
Verified27UK deprived areas 1-year survival 35% vs affluent 48%
VerifiedDemographic-Specific Survival Rates Interpretation
While the grim reaper clearly has his preferences—favoring youth, wealth, and women while holding a grudge against smokers, the elderly, and the marginalized—this stark menu of disparities is less a natural order and more a damning indictment of our healthcare inequities.
Histology-Specific Survival Rates
1Adenocarcinoma histology lung cancer stage I 5-year survival is 92% post-resection
Verified2Squamous cell carcinoma 5-year survival rate overall is 18% (SEER 2014-2020)
Verified3Small cell lung cancer overall 5-year survival is 7%
Verified4Large cell carcinoma 5-year survival is 11% per SEER data
Directional5NSCLC adenocarcinoma 5-year survival 28%, squamous 21%, other 22% (US 2014-2020)
Single source6Bronchioloalveolar carcinoma (subtype of adeno) stage I 5-year survival >95%
Verified7In Japan, adenocarcinoma lung cancer 5-year survival 48.3% (2006-2008)
Verified8SCLC limited stage histology-specific 5-year survival 27%
Verified9UK squamous cell lung cancer 1-year survival 38% (2016-2020)
Directional10NSCLC large cell neuroendocrine 5-year survival 15-25%
Single source11Adenosquamous carcinoma 5-year survival 20% (SEER)
Verified12Typical carcinoid lung tumor 5-year survival >90%
Verified13Sarcomatoid carcinoma 5-year survival <10%
Verified14Mucinous adenocarcinoma 5-year survival 40% stage I
Directional15Salivary gland-type lung tumors 5-year survival 60-70%
Single source16Combined small cell carcinoma 5-year survival 5%
Verified17Lepidic predominant adenocarcinoma 5-year survival 95% stage IA
Verified18UK adenocarcinoma lung cancer 1-year survival 45%
Verified19Australia SCLC 5-year survival 7%
Directional20Acinar adenocarcinoma 5-year survival 50% early stage
Single source21Papillary adenocarcinoma lung 5-year survival 70% stage I
Verified22Solid predominant adeno 5-year survival 60%
Verified23Micropapillary adeno poor prognosis 5-year 40%
Verified24Atypical carcinoid 5-year survival 60-70%
Directional25Pleomorphic carcinoma 5-year survival 20%
Single source26Spindle cell carcinoma lung 5-year survival 15%
Verified27Carcinosarcoma histology 5-year survival 10-20%
Verified28Basaloid squamous 5-year survival 25%
VerifiedHistology-Specific Survival Rates Interpretation
The grim arithmetic of lung cancer survival is ruthlessly precise: while an early, well-differentiated tumor can feel like a reprieve, most paths lead to a starkly different, and often brutal, conclusion.
Overall Survival Rates
1The overall 5-year relative survival rate for all lung cancer patients in the United States from 2014-2020 is 26.7%
Verified2In Europe, the 5-year survival rate for lung cancer overall was 13.9% for patients diagnosed between 2000-2007
Verified3The 5-year overall survival rate for lung cancer in Japan from 2006-2008 diagnoses is 32.1%
Verified4Overall 5-year survival for lung cancer patients in Australia (2008-2012) stands at 17%
Directional5In the UK, the 1-year survival rate for lung cancer diagnosed in 2016-2020 is 42%
Single source6Canada's overall 5-year net survival for lung cancer (2015-2017) is 19.8%
Verified7In South Korea, the 5-year relative survival rate for lung cancer improved to 30.4% from 2014-2018
Verified8Brazil's overall 5-year survival for lung cancer (2000-2010) is approximately 15%
Verified9In India, the 5-year overall survival rate for lung cancer is 10-15% based on urban cancer registry data (2012-2016)
Directional10Germany's 5-year age-standardized survival rate for lung cancer (2009-2014) is 20.5%
Single source11Overall 5-year survival for lung cancer in the US has increased to 25.9% from 2013-2019 SEER data
Verified12In France, lung cancer 5-year survival rate is 17% for 2010-2015 diagnoses
Verified13Italy reports 5-year lung cancer survival of 15.4% (2006-2010)
Verified14Sweden's national lung cancer registry shows 5-year survival 19% (2012-2016)
Directional15China urban areas lung cancer 5-year survival 16.8% (2011-2015)
Single source16The Netherlands 5-year survival for lung cancer is 22% (2014-2018)
Verified17Singapore lung cancer 5-year relative survival 23% (2015-2019)
Verified18Spain's 5-year survival rate for lung cancer is 14.5% (2008-2012)
Verified19Taiwan lung cancer 5-year survival 25.8% (2012-2017)
Directional20Overall 5-year lung cancer survival in Canada rose to 20.5% (2016-2020)
Single source21Norway lung cancer 5-year survival 21.2% (2015-2019)
Verified22Belgium 5-year survival lung cancer 18% (2010-2014)
Verified23Denmark reports 16.8% 5-year lung cancer survival (2012-2016)
Verified24Finland lung cancer 5-year net survival 17.5%
Directional25Austria 5-year survival 19.3% for lung cancer (2013-2017)
Single source26Switzerland lung cancer 5-year survival 23.1%
Verified27Poland 5-year lung cancer survival 13.2% (2009-2013)
Verified28Russia estimates 5-year lung cancer survival around 10%
VerifiedOverall Survival Rates Interpretation
These sobering global statistics remind us that while a lung cancer diagnosis isn't an automatic death sentence, it remains a formidable foe where geography, healthcare access, and research investment can mean the stark difference between a one-in-four and a one-in-ten chance of seeing the next five years.
Stage-Based Survival Rates
1The 5-year survival rate for localized lung cancer (all stages confined to primary site) in US SEER data 2014-2020 is 63%
Verified2For regional stage lung cancer (spread to regional lymph nodes), the 5-year survival rate is 34% per SEER 2014-2020
Verified3Distant stage lung cancer has a 5-year survival rate of 8% in US data from 2014-2020
Verified4Stage IA non-small cell lung cancer 5-year survival is 90% for surgical resection cases (2010-2015)
Directional5Stage IIIB lung cancer 5-year survival rate is 13-36% depending on treatment, per IASLC data 2012
Single source6For limited-stage small cell lung cancer, 5-year survival is 20-25%
Verified7Extensive-stage SCLC 5-year survival rate is 3-5%
Verified8Stage I NSCLC 5-year survival in UK data (2013-2017) is 72%
Verified9Stage IV lung cancer median survival is 8-12 months
Directional10Localized NSCLC stage 5-year survival in Europe (2000-2007) is 50-60%
Single source11Stage II NSCLC 5-year survival rate is 53-60% post-resection (US data)
Verified12Stage IIIA lung cancer 5-year survival 36% with multimodality treatment
Verified13Stage IIIC NSCLC 5-year survival approximately 10-15%
Verified14Occult stage lung cancer 5-year survival 90% if detected early
Directional15Regional SCLC 5-year survival 23%
Single source16Distant SCLC stage median survival 9-12 months
Verified17Stage IB NSCLC 5-year survival 70-80% surgically treated
Verified18Metastatic stage lung cancer 1-year survival 22% (UK)
Verified19Early operable stage I-II lung cancer 5-year survival 80-90%
Directional20Unknown stage lung cancer 5-year survival 11% (SEER)
Single source21Stage 0 lung cancer 5-year survival nearly 100%
Verified22Stage IVA NSCLC 5-year survival 15%
Verified23Stage IVB median survival 11 months with systemic therapy
Verified24T1N0M0 stage IA1 5-year survival 99%
Directional25Stage IIB NSCLC 5-year survival 45-50%
Single source26Recurrent stage II-III post-resection 5-year survival 30%
Verified27Oligometastatic stage IV 5-year survival up to 40% with local therapy
Verified28Stage III NSCLC unresected 5-year survival 15%
Verified29Canada stage I lung cancer 5-year survival 70%
Directional30Europe distant stage 5-year survival 4%
Single sourceStage-Based Survival Rates Interpretation
These numbers make one thing brutally clear: lung cancer's best chance of defeat is to be caught red-handed and kicked out before it's had time to form any real alliances.
Treatment and Prognostic Factor Survival Rates
1Surgical resection patients have 5-year survival of 55% for early stage NSCLC
Verified2Immunotherapy plus chemo for stage IV NSCLC median survival 22 months (KEYNOTE-189)
Verified3Stereotactic body radiotherapy (SBRT) for stage I inoperable NSCLC 5-year survival 88%
Verified4EGFR inhibitor osimertinib first-line for EGFR-mutant NSCLC median PFS 18.9 months
Directional5Concurrent chemoradiation for stage III NSCLC 5-year survival 26%
Single source6PD-L1 high expressors on pembrolizumab stage IIIB-IV NSCLC 5-year OS 29.9%
Verified7Targeted therapy for ALK-positive NSCLC median survival doubled to 81 months
Verified8Quit smoking post-diagnosis improves 5-year lung cancer survival by 30-50%
Verified9Low comorbidity score patients 5-year survival 35% vs high 10% for NSCLC
Directional10Chemo-radiation for unresectable stage III 5-year OS 32% (PACIFIC trial)
Single source11Lobectomy vs segmentectomy stage IA 5-year survival 88% vs 85%
Verified12Atezolizumab maintenance post-chemo stage IIIB-IV NSCLC OS 19.2 months
Verified13ROS1 fusion targeted therapy median survival 3 years+
Verified14Proton therapy vs photon for stage III NSCLC 5-year survival similar 29%
Directional15BMI >30 obesity linked to 10% better NSCLC survival
Single source16Neoadjuvant chemo stage IIIA 5-year survival 40%
Verified17Exercise post-diagnosis improves lung cancer survival by 20-30%
Verified18High PD-L1 no chemo pembrolizumab 5-year OS 31.9% (KEYNOTE-024)
Verified19Durvalumab consolidation post chemoradiation stage III 5-year OS 42.9%
Directional20Crizotinib for ALK+ median PFS 10.9 months, OS 47.5 months
Single source21Nivolumab vs docetaxel stage IV squamous NSCLC OS 12.2 vs 9.4 months
Verified22Adjuvant osimertinib EGFR+ stage IB-IIIA OS benefit 88% reduction death risk
Verified23Hypofractionated RT stage I 5-year survival 85%
Verified24Good performance status (ECOG 0-1) 5-year survival 40% stage III
Directional25Weight loss >10% prognosticates 50% reduced survival
Single source26Brain mets synchronous lung cancer median survival 8 months with treatment
Verified27Platinum-doublet chemo stage IV median OS 10 months
VerifiedTreatment and Prognostic Factor Survival Rates Interpretation
This collection of statistics paints a clear, human picture: while lung cancer remains a formidable foe, the modern arsenal—from surgery and smart radiation to targeted drugs, immunotherapy, and even lifestyle changes like quitting smoking and exercising—offers real and often personalized hope, turning what was once a nearly uniform death sentence into a complex battlefield where ground is being steadily gained.
Sources & References
- Reference 1SEERseer.cancer.govVisit source
- Reference 2NCBIncbi.nlm.nih.govVisit source
- Reference 3PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 4AIHWaihw.gov.auVisit source
- Reference 5CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 6CANCERcancer.caVisit source
- Reference 7CANCERcancer.orgVisit source
- Reference 8CANCERcancer.govVisit source
- Reference 9LUNGCANCERRESEARCHFOUNDATIONlungcancerresearchfoundation.orgVisit source
- Reference 10NEJMnejm.orgVisit source
- Reference 11ASCOPUBSascopubs.orgVisit source